Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 841 entries
Sorted by: Best Match Show Resources per page
Transient loss of vision as the presenting symptom of papillary fibroelastoma of aortic valve.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology

Shirani J, Bradlow JA, Metveyeva P, Losada M, Factor SM, Strom JA, Sisto D.
PMID: 25991541
Cardiovasc Pathol. 1997 Jul;6(4):237-40. doi: 10.1016/S1054-8807(96)00137-8.

Cardiac papillary fibroelastomas are benign endocardial papillomas. They may arise from atrial or ventricular endocardium but most commonly are located in cardiac valves. Their papillary structure, with loose, friable projections, results in a high tendency for embolism. Tumor fragments...

Cite
Shirani J, Bradlow JA, Metveyeva P, et al. Transient loss of vision as the presenting symptom of papillary fibroelastoma of aortic valve. Cardiovasc Pathol. 1997;6(4):237-40doi: 10.1016/S1054-8807(96)00137-8.
Shirani, J., Bradlow, J. A., Metveyeva, P., Losada, M., Factor, S. M., Strom, J. A., & Sisto, D. (1997). Transient loss of vision as the presenting symptom of papillary fibroelastoma of aortic valve. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology, 6(4), 237-40. https://doi.org/10.1016/S1054-8807(96)00137-8
Shirani, J, et al. "Transient loss of vision as the presenting symptom of papillary fibroelastoma of aortic valve." Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology vol. 6,4 (1997): 237-40. doi: https://doi.org/10.1016/S1054-8807(96)00137-8
Shirani J, Bradlow JA, Metveyeva P, Losada M, Factor SM, Strom JA, Sisto D. Transient loss of vision as the presenting symptom of papillary fibroelastoma of aortic valve. Cardiovasc Pathol. 1997 Jul;6(4):237-40. doi: 10.1016/S1054-8807(96)00137-8. PMID: 25991541.
Copy Download .nbib Format: NLM
Reconfigurable directional lasing modes in cavities with generalized PT symmetry.

Physical review letters

Lee JM, Factor S, Lin Z, Vitebskiy I, Ellis FM, Kottos T.
PMID: 25014817
Phys Rev Lett. 2014 Jun 27;112(25):253902. doi: 10.1103/PhysRevLett.112.253902. Epub 2014 Jun 25.

We introduce a new family of generalized PT-symmetric cavities that involve gyrotropic elements and support reconfigurable unidirectional lasing modes. We derive conditions for which these modes exist and investigate a simple electronic circuit that experimentally demonstrates their feasibility in...

Cite
Lee JM, Factor S, Lin Z, et al. Reconfigurable directional lasing modes in cavities with generalized PT symmetry. Phys Rev Lett. 2014;112(25):253902doi: 10.1103/PhysRevLett.112.253902.
Lee, J. M., Factor, S., Lin, Z., Vitebskiy, I., Ellis, F. M., & Kottos, T. (2014). Reconfigurable directional lasing modes in cavities with generalized PT symmetry. Physical review letters, 112(25), 253902. https://doi.org/10.1103/PhysRevLett.112.253902
Lee, J M, et al. "Reconfigurable directional lasing modes in cavities with generalized PT symmetry." Physical review letters vol. 112,25 (2014): 253902. doi: https://doi.org/10.1103/PhysRevLett.112.253902
Lee JM, Factor S, Lin Z, Vitebskiy I, Ellis FM, Kottos T. Reconfigurable directional lasing modes in cavities with generalized PT symmetry. Phys Rev Lett. 2014 Jun 27;112(25):253902. doi: 10.1103/PhysRevLett.112.253902. Epub 2014 Jun 25. PMID: 25014817.
Copy Download .nbib Format: NLM
Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism.

Hematology. American Society of Hematology. Education Program

Ansell JE, Weitz JI, Comerota AJ.
PMID: 11701546
Hematology Am Soc Hematol Educ Program. 2000;266-284. doi: 10.1182/asheducation-2000.1.266.

This review focuses on antithrombotic therapy for venous thromboembolism and covers a diverse range of topics including a discussion of emerging anticoagulant drugs, a renewed focus on thrombolytic agents for selected patients, and an analysis of the factors leading...

Cite
Ansell JE, Weitz JI, Comerota AJ. Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology Am Soc Hematol Educ Program. 2000;266-284doi: 10.1182/asheducation-2000.1.266.
Ansell, J. E., Weitz, J. I., & Comerota, A. J. (2000). Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology. American Society of Hematology. Education Program, 266-284. https://doi.org/10.1182/asheducation-2000.1.266
Ansell, Jack E., et al. "Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism." Hematology. American Society of Hematology. Education Program vol. (2000): 266-284. doi: https://doi.org/10.1182/asheducation-2000.1.266
Ansell JE, Weitz JI, Comerota AJ. Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology Am Soc Hematol Educ Program. 2000;266-284. doi: 10.1182/asheducation-2000.1.266. PMID: 11701546.
Copy Download .nbib Format: NLM
Potential for a New Coronary Thrombolytic Plateau.

Journal of thrombosis and thrombolysis

Topol EJ.
PMID: 10602553
J Thromb Thrombolysis. 1996;3(2):127-134. doi: 10.1007/BF00132405.

The GUSTO-I trial provided definitive evidence that early and complete thrombolysis are closely associated with clinical outcome. However, in this trial the best thrombolytic strategy, consisting of accelerated t-PA, aspirin, and heparin, only yielded restoration of brisk flow (TIMI...

Cite
Topol EJ. Potential for a New Coronary Thrombolytic Plateau. J Thromb Thrombolysis. 1996;3(2):127-134doi: 10.1007/BF00132405.
Topol, E. J. (1996). Potential for a New Coronary Thrombolytic Plateau. Journal of thrombosis and thrombolysis, 3(2), 127-134. https://doi.org/10.1007/BF00132405
Topol. "Potential for a New Coronary Thrombolytic Plateau." Journal of thrombosis and thrombolysis vol. 3,2 (1996): 127-134. doi: https://doi.org/10.1007/BF00132405
Topol EJ. Potential for a New Coronary Thrombolytic Plateau. J Thromb Thrombolysis. 1996;3(2):127-134. doi: 10.1007/BF00132405. PMID: 10602553.
Copy Download .nbib Format: NLM
New developments in anticoagulation for atrial fibrillation.

Current treatment options in cardiovascular medicine

Usman MH, Notaro LA, Patel H, Ezekowitz MD.
PMID: 18814828
Curr Treat Options Cardiovasc Med. 2008 Sep;10(5):388-97. doi: 10.1007/s11936-008-0030-0.

The incidence of stroke in patients with atrial fibrillation (AF) is five times greater than that in age-matched controls. Warfarin reduces this incidence by two thirds and is the most effective agent for this indication. However, despite its efficacy,...

Cite
Usman MH, Notaro LA, Patel H, et al. New developments in anticoagulation for atrial fibrillation. Curr Treat Options Cardiovasc Med. 2008;10(5):388-97doi: 10.1007/s11936-008-0030-0.
Usman, M. H., Notaro, L. A., Patel, H., & Ezekowitz, M. D. (2008). New developments in anticoagulation for atrial fibrillation. Current treatment options in cardiovascular medicine, 10(5), 388-97. https://doi.org/10.1007/s11936-008-0030-0
Usman, M Haris U, et al. "New developments in anticoagulation for atrial fibrillation." Current treatment options in cardiovascular medicine vol. 10,5 (2008): 388-97. doi: https://doi.org/10.1007/s11936-008-0030-0
Usman MH, Notaro LA, Patel H, Ezekowitz MD. New developments in anticoagulation for atrial fibrillation. Curr Treat Options Cardiovasc Med. 2008 Sep;10(5):388-97. doi: 10.1007/s11936-008-0030-0. PMID: 18814828.
Copy Download .nbib Format: NLM
Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism.

Expert review of pharmacoeconomics & outcomes research

Wade WE, Spruill WJ.
PMID: 20528310
Expert Rev Pharmacoecon Outcomes Res. 2007 Jun;7(3):227-37. doi: 10.1586/14737167.7.3.227.

Fondaparinux sodium is the first in a new class of anticoagulants that selectively inhibits Factor Xa. It produces a predictable pharmacologic response, obviating the need for coagulation monitoring. Additionally, this agent does not bind to platelet Factor 4, thereby...

Cite
Wade WE, Spruill WJ. Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism. Expert Rev Pharmacoecon Outcomes Res. 2007;7(3):227-37doi: 10.1586/14737167.7.3.227.
Wade, W. E., & Spruill, W. J. (2007). Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism. Expert review of pharmacoeconomics & outcomes research, 7(3), 227-37. https://doi.org/10.1586/14737167.7.3.227
Wade, William E, and Spruill, William J. "Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism." Expert review of pharmacoeconomics & outcomes research vol. 7,3 (2007): 227-37. doi: https://doi.org/10.1586/14737167.7.3.227
Wade WE, Spruill WJ. Fondaparinux sodium in the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism. Expert Rev Pharmacoecon Outcomes Res. 2007 Jun;7(3):227-37. doi: 10.1586/14737167.7.3.227. PMID: 20528310.
Copy Download .nbib Format: NLM
Future therapies for the prevention and treatment of venous and arterial thrombosis.

Expert opinion on investigational drugs

McKean ML, Adelman SJ.
PMID: 15991961
Expert Opin Investig Drugs. 1998 May;7(5):687-90. doi: 10.1517/13543784.7.5.687.

The incidence of thrombosis as a complication of invasive surgery, in cancer patients, as a cause or complication of stroke, acute myocardial infarction (AMI), thrombolysis, unstable angina (UA) or angioplasty is substantial. To better serve this patient population in...

Cite
McKean ML, Adelman SJ. Future therapies for the prevention and treatment of venous and arterial thrombosis. Expert Opin Investig Drugs. 1998;7(5):687-90doi: 10.1517/13543784.7.5.687.
McKean, M. L., & Adelman, S. J. (1998). Future therapies for the prevention and treatment of venous and arterial thrombosis. Expert opinion on investigational drugs, 7(5), 687-90. https://doi.org/10.1517/13543784.7.5.687
McKean, M L, and Adelman, S J. "Future therapies for the prevention and treatment of venous and arterial thrombosis." Expert opinion on investigational drugs vol. 7,5 (1998): 687-90. doi: https://doi.org/10.1517/13543784.7.5.687
McKean ML, Adelman SJ. Future therapies for the prevention and treatment of venous and arterial thrombosis. Expert Opin Investig Drugs. 1998 May;7(5):687-90. doi: 10.1517/13543784.7.5.687. PMID: 15991961.
Copy Download .nbib Format: NLM
Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness.

Parkinsonism & related disorders

Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ.
PMID: 18591048
Parkinsonism Relat Disord. 1997 Jan;3(1):1-6. doi: 10.1016/s1353-8020(96)00042-9.

Clinical trials designed to evaluate the efficacy of new anti-parkinsonian agents often employ an 'add-on' protocol in which patients with motor fluctuations on levodopa are randomized to receive active medication or placebo. Levodopa doses may not be increased, but...

Cite
Hauser RA, Zesiewicz TA, Factor SA, et al. Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. Parkinsonism Relat Disord. 1997;3(1):1-6doi: 10.1016/s1353-8020(96)00042-9.
Hauser, R. A., Zesiewicz, T. A., Factor, S. A., Guttman, M., & Weiner, W. J. (1997). Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. Parkinsonism & related disorders, 3(1), 1-6. https://doi.org/10.1016/s1353-8020(96)00042-9
Hauser, R A, et al. "Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness." Parkinsonism & related disorders vol. 3,1 (1997): 1-6. doi: https://doi.org/10.1016/s1353-8020(96)00042-9
Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ. Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. Parkinsonism Relat Disord. 1997 Jan;3(1):1-6. doi: 10.1016/s1353-8020(96)00042-9. PMID: 18591048.
Copy Download .nbib Format: NLM
Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban.

Expert review of pharmacoeconomics & outcomes research

Ivanovic N, Beinema M, Brouwers JR, Naunton M, Postma MJ.
PMID: 20528430
Expert Rev Pharmacoecon Outcomes Res. 2007 Feb;7(1):49-58. doi: 10.1586/14737167.7.1.49.

This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as...

Cite
Ivanovic N, Beinema M, Brouwers JR, et al. Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban. Expert Rev Pharmacoecon Outcomes Res. 2007;7(1):49-58doi: 10.1586/14737167.7.1.49.
Ivanovic, N., Beinema, M., Brouwers, J. R., Naunton, M., & Postma, M. J. (2007). Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban. Expert review of pharmacoeconomics & outcomes research, 7(1), 49-58. https://doi.org/10.1586/14737167.7.1.49
Ivanovic, Natasa, et al. "Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban." Expert review of pharmacoeconomics & outcomes research vol. 7,1 (2007): 49-58. doi: https://doi.org/10.1586/14737167.7.1.49
Ivanovic N, Beinema M, Brouwers JR, Naunton M, Postma MJ. Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban. Expert Rev Pharmacoecon Outcomes Res. 2007 Feb;7(1):49-58. doi: 10.1586/14737167.7.1.49. PMID: 20528430.
Copy Download .nbib Format: NLM
Transitions of care in anticoagulated patients.

Journal of multidisciplinary healthcare

Michota F.
PMID: 23818798
J Multidiscip Healthc. 2013 Jun 20;6:215-28. doi: 10.2147/JMDH.S44068. Print 2013.

Anticoagulation is an effective therapeutic means of reducing thrombotic risk in patients with various conditions, including atrial fibrillation, mechanical heart valves, and major surgery. By its nature, anticoagulation increases the risk of bleeding; this risk is particularly high during...

Cite
Michota F. Transitions of care in anticoagulated patients. J Multidiscip Healthc. 2013;6:215-28doi: 10.2147/JMDH.S44068.
Michota, F. (2013). Transitions of care in anticoagulated patients. Journal of multidisciplinary healthcare, 6215-28. https://doi.org/10.2147/JMDH.S44068
Michota, Franklin. "Transitions of care in anticoagulated patients." Journal of multidisciplinary healthcare vol. 6 (2013): 215-28. doi: https://doi.org/10.2147/JMDH.S44068
Michota F. Transitions of care in anticoagulated patients. J Multidiscip Healthc. 2013 Jun 20;6:215-28. doi: 10.2147/JMDH.S44068. Print 2013. PMID: 23818798; PMCID: PMC3693821.
Copy Download .nbib Format: NLM
Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Fung LS, Klockau C.
PMID: 22477802
J Pediatr Pharmacol Ther. 2010 Apr;15(2):119-25.

OBJECTIVE: The objective of this dose range study is to expand on the relationship between age and weight-based doses of enoxaparin and resulting levels of anti-factor Xa (anti-Xa) in pediatric patients. The primary outcome of this study is to...

Cite
Fung LS, Klockau C. Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients. J Pediatr Pharmacol Ther. 2010;15(2):119-25
Fung, L. S., & Klockau, C. (2010). Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 15(2), 119-25.
Fung, Lela S, and Klockau, Christopher. "Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 15,2 (2010): 119-25.
Fung LS, Klockau C. Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients. J Pediatr Pharmacol Ther. 2010 Apr;15(2):119-25. PMID: 22477802; PMCID: PMC3018183.
Copy Download .nbib Format: NLM
Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Fung LS, Klockau C.
PMID: 22477802
J Pediatr Pharmacol Ther. 2010 Apr;15(2):119-25.

OBJECTIVE: The objective of this dose range study is to expand on the relationship between age and weight-based doses of enoxaparin and resulting levels of anti-factor Xa (anti-Xa) in pediatric patients. The primary outcome of this study is to...

Cite
Fung LS, Klockau C. Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients. J Pediatr Pharmacol Ther. 2010;15(2):119-25
Fung, L. S., & Klockau, C. (2010). Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 15(2), 119-25.
Fung, Lela S, and Klockau, Christopher. "Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 15,2 (2010): 119-25.
Fung LS, Klockau C. Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients. J Pediatr Pharmacol Ther. 2010 Apr;15(2):119-25. PMID: 22477802; PMCID: PMC3018183.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 841 entries